AC
ODT

Apogem Capital’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Apogem Capital’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,931
Closed -$31K – 206
2021
Q4 		$31K Buy
+22,931
New +$54.2K 0.02% 173

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Apogem Capital's ODT Position: Q1 2022 in Review

Apogem Capital sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 22,931 shares — an estimated $31K sold.

Apogem Capital first reported a position in ODT in Q4 2021 and held it in 1 quarter. The position peaked at $31K in Q4 2021. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Apogem Capital reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Apogem Capital sold 22,931 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $31K.
  • Apogem Capital first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Apogem Capital's Odonate Therapeutics, Inc. Common Stock position peaked at $31K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Apogem Capital's 13F filing for Q1 2022, filed 16 May 2022.